Features | Partner Sites | Information | LinkXpress
Sign In
FOCUS DIAGNOSTICS, INC.
RANDOX LABORATORIES
GLOBETECH PUBLISHING

Novel Candidate Protein Biomarkers Identified for Gastric Cancer

By Labmedica International staff writers
Posted on 25 Mar 2014
Image: Ultra nano-liquid chromatography system (Photo courtesy of Eksigent).
Image: Ultra nano-liquid chromatography system (Photo courtesy of Eksigent).
The early detection of stomach or gastric cancer (GC) has been revealed with the identification of four new biomarkers in the blood of human cancer patients.

This poor outcome of GC can be attributed to an extended asymptomatic period associated with this cancer, and difficulty in the detection of early stage gastric adenocarcinoma when treatment could improve long term survival of patients.

Scientists at the University of Adelaide (Australia) collected serum samples from 37 preoperative GC patients with intestinal type gastric adenocarcinoma. There were 10 females, with a mean age range of 69 ± 10 years and 17 males with a mean age range of 66 ± 11 years. In the cohort were 11 early stage cancer patients, and the controls included healthy and noncancerous patients with other gastric disease.

Enzyme-linked immunosorbent assays (ELISA) were performed for four proteins afamin, clusterin, haptoglobin and vitamin D binding protein (VDBP) and obtained from USCN Life Science Inc., (Wuhan, China). Ten GC and 10 controls serum samples were analyzed with multiple reaction monitoring high resolution mass spectrometry (MRM-HR). These serum samples were run on Triple TOF 5600 mass spectrometer (AB Sciex; Framingham, MA, USA) with an Ultra nano-liquid chromatography (LC) system (Eksigent; Redwood City, CA, USA).

The analysis of the ELISA results showed that the sensitivity and specificity values represented as Area Under the Curve (AUC) were: 0.94 for clusterin, 0.84 for VDBP, 0.58 for haptoglobin, and 0.52 for afamin. The MRM-HR data when analyzed revealed a trend for differential regulation of afamin, clusterin and VDBP. MRM-HR analysis revealed a significant higher abundance of haptoglobin in GC patients which was similar to that observed in the results from the ELISA. All four proteins were individually superior to a current clinical marker CA72-4 in discriminating stomach cancer from healthy controls.

The authors concluded that the differential regulation of four serum proteins in gastric cancer patients compared with normal healthy individuals were found with clusterin, VDBP and afamin down-regulated, and haptoglobin up-regulated in serum from GC versus benign GI disease cases. Peter Hoffmann, PhD, a professor at the University of Adelaide and senior author of the study said, “Stomach cancer is typically without symptoms in the early stages so most cancers are not diagnosed until the later stages, and the survival rates are therefore low. A noninvasive, inexpensive screening technique through a simple blood test for the early detection of stomach cancer would make a huge difference in the survival outcomes for people with this disease.” The study was published on February 7, 2014, in the journal Biochimica et Biophysica Acta.

Related Links:

University of Adelaide
AB Sciex
Eksigent



DiagCor Bioscience
Sekisui Diagnostics
VIRCELL
comments powered by Disqus
Life Technologies

Channels

Immunology

view channel
Image: The fluorescence-activated cell sorting FACSCanto II flow cytometer (Photo courtesy of BD Biosystems).

Flow Cytometry Detects Lymphoproliferative Disorders in Fluid Specimens

Immunophenotypic analysis of hematopoietic cell populations by flow cytometry has emerged as a useful ancillary study in the diagnostic evaluation of serous effusions and cerebrospinal fluids (CSFs).... Read more

Pathology

view channel
Image: Histopathology of increased endomysial connective tissue from a patient with Duchenne Muscular Dystrophy. Necrotic fibers arrowed (Photo courtesy of Washington University in St. Louis).

New Partnership Designed to Automate Dystrophin Measurement

A developer of innovative ribonucleic acid (RNA)-based therapeutics, Sarepta Therapeutics, Inc. ( Cambridge, MA, USA), and a leading tissue-based companion diagnostics firm, Flagship Biosciences LLC (Boulder,... Read more

Lab Tech.

view channel
Image: A technical breakthrough for DNA imaging has been achieved that should quicken diagnosis of diseases for which analysis of DNA from single-cells is critical, such as early stage cancers and various pre-natal conditions (Photo courtesy of McGill University and Génome Québec Innovation Center).

Breakthrough DNA Analysis Technology to Hasten Problem Diagnosis

Researchers have achieved a technical breakthrough that should result in speedier diagnosis of diseases for which analysis of DNA from single-cells is critical, such as early stage cancers and various... Read more

Industry News

view channel

Most IVD Sector Companies Look Outside the EU and USA for Growth

Kalorama Information (New York City, NY, USA) has now published the 9th edition of its biennial market research report “Worldwide Market for In Vitro Diagnostics,” revealing estimates from its survey of the in vitro diagnostics (IVD) industry – presenting the trends, technologies, customer needs, and major suppliers with... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.